Compare Medpace Holdings Inc (MEDP) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Quantumscape Corp — how do they compare? Medpace Holdings Inc trades at $601.1 (market cap $16.90B), while Quantumscape Corp trades at $6.35 (market cap $3.90B). The key difference: Medpace Holdings Inc is far larger — about 4.3× Quantumscape Corp's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| MEDP | QS | |
|---|---|---|
Market Cap | $16.90B | $3.90B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $18.44 |
52-Week Low | $393.42 | $4.89 |
Enterprise Value | $16.52B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
QuantumScape trades at $6.34, up 2.42% today, with a bullish technical signal but mixed sentiment. The company remains pre-revenue, reporting a net loss of $435.05M in 2025, with negative ROE and ROA. Recent earnings showed beats on EPS estimates, but commercialization timelines have been delayed to 2029, fueling investor skepticism.
The outlook hinges on successful battery technology commercialization by 2029, presenting high-risk, high-reward potential. Key risks include execution delays, intense competition, and reliance on financing. Analyst consensus is cautious, with no buy ratings, reflecting significant uncertainty around the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
